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Immune mediated therapies (IMT), such as anti-CTLA-4
and anti-PD-1/PD-L1, are showing significant promise in
the treatment of solid tumors. However, although these
treatments can show significant overall benefit, a subset of
patients fails to respond. It is believed that activity in these
patients is limited by a lack of immune priming or by
immunosuppression. Combination with molecular
targeted therapies has the potential to overcome these
hurdles to response and maximize patient benefit. In order
to select the best combination partners, a greater under-
standing is needed of how other therapies affect the
immune system both directly, through effects on leuko-
cytes, and indirectly, through effects on tumor immuno-
genicity and induction of tumor cell death.
Selumetinib (AZD6244, ARRY-142886) is a potent inhi-
bitor of the mitogen-activated protein/extracellular signal-
regulated kinase kinases 1/2 (MEK1/2), involved in the
activation of signaling pathways which regulates cellular
growth, proliferation and survival. Given that these path-
ways are often found aberrantly activated in human
tumours and also play key roles in the regulation of immu-
nological processes, it is difficult to predict the combina-
torial effect of MEK1/2 inhibition and IMT. Here we
detail a systematic approach taken towards examining the
effects of MEK1/2 inhibition on tumour immunogenicity
in vitro and in vivo and the direct effects it may have on
the function of the immune system. We also present
preclinical data demonstrating the anti-tumour activity of
combining selumetinib and IMT mAbs in a syngeneic
mouse model and report on possible mechanisms of
synergism in promoting an anti-tumour immune response
through promotion of antigen presentation.
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